Home › Hemoglobinopathies › NCT07373639
A Long-term Follow-up Study in Patients Who Received BEAM-101
A Long-term Follow-up Study in Patients With Hemoglobinopathy Who Received Autologous CD34+ Edited Hematopoietic Stem Cells
Who can join
Ages 14 to 37 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Have received BEAM-101 in Study BTX-AUT-001 and are in the process of completing that study's end-of-study (EOS) visit. 2. Provide signed, written informed consent according to local institutional review board (IRB)/independent ethics committee (IEC) and institutional requirements. Exclusion Criteria: * There are no exclusion criteria for this study.
About the study
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).
What is being tested
- Long-Term Follow-up Study of patients who received BEAM-101 (drug)
Sponsor: Beam Therapeutics Inc. · Participants: 50 · Started: Dec 15, 2025
Contact the study team
- Medical Information · Phone: +1 857-327-8641
Official record on ClinicalTrials.gov — NCT07373639
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.